NEWSROOM | Galderma

Galderma debuts the Sensitive Skincare Faculty, a global expert group to improve understanding and management of sensitive skin

Galderma showcases its continued commitment to innovation in dermatology with new data to be presented at 2022 EADV congress

Galderma delivers strong H1 2022 results and continued innovation across its leading dermatology portfolio

Galderma and Children’s Skin Disease Foundation Celebrate Decade-Long Partnership

Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis

Galderma announces positive results in two phase III studies for a novel liquid formulation botulinumtoxinA (RelabotulinumtoxinA) for the treatment of glabellar lines (frown) and lateral canthal lines (crow’s feet)

Galderma to present new findings from innovative product portfolio at the 2022 VCS Annual Symposium

Galderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea

Actinic Keratosis prevention campaign encourages everyone to ‘FACE THE FACTS’

Galderma to present extensive new clinical data across its portfolio of neuromodulators, fillers and biostimulators at the IMCAS World Congress 2022

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

Cetaphil® debuts global sensitive skin awareness initiative